Skip to main content
Premium Trial:

Request an Annual Quote

Devyser Diagnostics Fully Acquires Data Analysis Software Maker SmartSeq

NEW YORK — Swedish molecular diagnostics firm Devyser Diagnostics said on Monday that it has exercised an option to fully acquire SmartSeq, an Italian developer of data analysis software, for €835,000 ($942,500) in cash and stock.

SmartSeq offers Amplicon Suite, a software-as-a-service that enables genetic test data uploading, analysis, and interpretation, as well as results reporting. It is primarily sold to Devyser, which bundles it with a reagent kit, but also marketed to other customers.

Under the terms of the deal, Devyser acquired the remaining 70.1 percent of SmartSeq in exchange for €242,150 in cash and €592,850 in newly issued Devyser shares. In late 2018, Devyser paid €12,558 for 29.9 percent of SmartSeq and an option to buy the rest of the company.

"SmartSeq has a high degree of expertise in software development for data analysis and its software is a key component in our offering in genetic testing," Devyser CEO Fredrik Alpsten said in a statement. "The acquisition strengthens our gross margin as we can now supply the software ourselves instead of purchasing it from SmartSeq."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.